Q4 2018: Growth in fourth quarter closes the year

Significant events in the fourth quarter
• Fourth-quarter net sales rose to MSEK 163, up 36%, or MSEK 43 compared with the year-on-year period, due to continued recovery from a customer-specific destocking programme
• First commercial order after the introduction of Probi’s product to improve bone health in postmenopausal women – Probi® Osteo
• Promising initial results from clinical trials to evaluate the effects of Probi’s strains on physical performance and acute stress
• Tom Rönnlund appointed new CEO as of January 1, 2019 and Henrik Lundkvist new CFO as of January 7, 2019
• Board of Directors propose that the 2019 Annual General Meeting resolves that no dividends will be paid for the 2018 financial year

Financial overview

MSEK   Full-year 2018   Full-year 2017
Net sales   604.1   612.2
Net sales growth, constant currency, %   -2.2%   38.2%
Gross margin, %   46.0%   45.4%
EBITDA   154.9   157.3
EBITDA margin, %   25.6%   25.7%
Operating profit (EBIT)   101.1   104.1
Net income   76.3   69.1
Earnings per share before and after dilution, SEK   6.69   6.06
Share price on closing day, SEK   360.00   340.00
Market cap on closing day   4,101.9   3,874.0
See note 5 for definitions of ratios not defined according to IFRS         

Invitation to teleconference
Date: 13 February 2019
Time: 10:00 a.m.
Phone: +46 8 56 64 27 07
Participants from Probi:
Tom Rönnlund, CEO:
Henrik Lundkvist, CFO

The presentation is available at www.probi.se and www.financialhearings.com

Tom Rönnlund, CEO: Phone: +46 (0)46 286 89 40, E-mail: trd@probi.com
Henrik Lundkvist, CFO: Phone: +46 (0)46 286 89 41, E-mail: henrik.lundkvist@probi.com

This information is information that Probi AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 13 February 2019 at 8:00 a.m. CET. This a translation of the Swedish version of the interim report. When in doubt, the Swedish wording prevails.

About Probi
Probi AB is a Swedish publicly traded bioengineering company. Probi’s vision is to help people live healthier lives by delivering effective and well-documented probiotics, with proven health benefits based on scientific research.
Founded by scientists in Sweden in 1991, Probi is a multinational company, active in more than 40 markets around the world and holding over 400 patents worldwide. In 2018, Probi had net sales of MSEK 604. The Probi share is listed on Nasdaq Stockholm, Mid Cap. Probi had about 4,000 shareholders on December 31, 2018.


About Us

Probi AB is a Swedish publicly traded biotechnology company that develops effective and well-documented probiotics. Through its research, Probi has created a strong product portfolio in the gastrointestinal health and immune system areas. The products are available to consumers in more than 40 countries worldwide. The customers are leading food, health-product and pharmaceutical companies in the Functional Food and Consumer Healthcare segments. The Probi share is listed on NASDAQ OMX Stockholm, Mid-cap. Read more on www.probi.se.


Documents & Links